Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
A review of the major findings presented at the Annual Meeting of the American Association for the Study of Liver Diseases in San Francisco
Hepatitis C affects more than just the liver. Hep C can have serious health impacts long before there are signs of advanced liver disease.
Compared with their HIV-negative peers, HIV-positive individuals have higher rates of treatment for a host of health problems.
Highlights from HIV and hepatitis C research presented at the 2018 Conference on Retroviruses and Opportunistic Infections (CROI) in Boston
March is National Kidney Month, and an opportune time to look at hepatitis C and the kidneys.
A pooled analysis of numerous studies found the safety and efficacy of the regimen was comparable between those under and those over 65.
The hepatitis C regimen was tested in a small group with severe kidney impairment.
A promising new regimen that will address unmet needs for this population is poised for FDA approval.
An analysis of forty-two clinical trials of all the approved direct acting antiviral HCV regimens.
A hep C cure in those with HIV is tied to a lower rate of death, AIDS-defining illnesses, advanced cirrhosis and liver cancer.
The liver disease non-alcoholic steatohepatitis (NASH) is tied to kidney disease.
Among people with HIV, injection drug users have a higher rate of end-stage liver and kidney disease.
Curing hepatitis C virus (HCV) is associated with a reduced risk of death, kidney disease and diabetes.
American singer, songwriter and performer Natalie Cole died December 31, 2015
Hepatitis C treatment for those who also have HIV, advanced liver disease or other major health challenges is a delicate science.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.